6-Methyl-4.5.6.7-tetrahydro-imidazolo<5.4-c>pyridin | 10517-40-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-Methyl-4.5.6.7-tetrahydro-imidazolo<5.4-c>pyridin
• 英文别名: 5-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine；5-Methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine；5-methyl-3,4,6,7-tetrahydroimidazo[4,5-c]pyridine
• CAS: 10517-40-5
• 化学式: C₇H₁₁N₃
• mdl: MFCD13176239
• 分子量: 137.184
• InChiKey: IXEUYAHNQXAWNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  31.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE
  申请人：Horiuchi Yoshihiro

  公开号：US20120225876A1

  公开（公告）日：2012-09-06

  Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R 1a and R 1b may be the same or different and each independently represents a C 1-6 alkyl group which may be substituted by one to three halogen atoms; m and n each independently represents an integer of 0-5; X 1 represents a hydroxyl group or an aminocarbonyl group; Z 1 represents a single bond or the like; and R 2 represents an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group or the like.)

  公开了一种由公式(1)表示的化合物或其药理可接受的盐(在公式中，A代表由公式(A-1)表示的基团；R1a和R1b可以相同或不同，每个独立地表示一个可以由一个到三个卤素原子取代的C1-6烷基；m和n各自独立地表示0-5之间的整数；X1代表羟基或氨基甲酰基；Z1代表单键等；R2代表一个可选地取代的C1-6烷基，一个可选地取代的C6-10芳基等)。
• SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES
  申请人：Hoffmann Matthias

  公开号：US20110201608A1

  公开（公告）日：2011-08-18

  The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R 1 denotes a group A selected from among —O—R 3 , —NR 3 R 4 , —CR 3 R 4 R 5 , -(ethyne)-R 3 , —S—R 3 , —SO—R 3 and SO 2 —R 3 or R 1 denotes a group B selected from among C 6-10 -aryl, five- to ten-membered, mono- or bicyclic heteroaryl with 1-3 heteroatoms selected independently of one another from among N, O and S; while this heteroaryl is linked to the structure according to formula 1 via either a C atom or an N atom, three- to ten-membered, mono- or bicyclic, saturated or partially saturated heterocyclic group with 1-3 heteroatoms selected independently of one another from among N, O and S, while this heterocyclic group is linked to the structure according to formula 1 via either a C atom or an N atom, and 5- to 11-membered spiro group which may optionally contain 1, 2 or 3 heteroatoms selected independently of one another from among N, O and S, while this spiro group is linked to the structure according to formula 1 via either a C atom or an N atom, while this group B may optionally be substituted as described in claim 1 and wherein R 2 is and R 3 , R 4 , R 5 , R 6 , R 6′ , R 7 , R 8 , R 9 , R 10 , V, n and m may have the meanings given in claim 1 , as well as pharmaceutical compositions containing these compounds.

  该发明涉及公式1的新取代萘啉类化合物，以及其药理学上可接受的盐、对映体、对映异构体、外消旋体、水合物或溶剂合物，其中R1表示从以下选取的A基团，包括—O—R3、—NR3R4、—CR3R4R5、-(乙炔)-R3、—S—R3、—SO—R3和SO2—R3，或R1表示从以下选取的B基团，包括C6-10-芳基、含有1-3个异原子（N、O和S）的五至十元杂环芳基，而此杂环芳基通过碳原子或氮原子与公式1中的结构连接，含有1-3个异原子（N、O和S）的三至十元杂环饱和或部分饱和环族基团，而此杂环基团通过碳原子或氮原子与公式1中的结构连接，以及可能含有1、2或3个异原子（N、O和S）的五至十一元螺环基团，而此螺环基团通过碳原子或氮原子与公式1中的结构连接，其中该B基团可以选择地按照权利要求1中所述进行取代，R2为，R3、R4、R5、R6、R6′、R7、R8、R9、R10、V、n和m的含义如权利要求1中所述，以及含有这些化合物的药物组合物。
• NOVEL THIENOPYRROLE COMPOUNDS
  申请人：Wishart Neil

  公开号：US20110152243A1

  公开（公告）日：2011-06-23

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  该发明提供了公式（I）的化合物，包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可用于治疗免疫和肿瘤疾病。
• [EN] PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS<br/>[FR] DÉRIVÉS PYRAZOLO[1, 5-A]PYRIMIDINE EN TANT QU'INHIBITEURS DE MTOR
  申请人：SCHERING CORP

  公开号：WO2010118207A1

  公开（公告）日：2010-10-14

  The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.

  本发明提供了使用吡唑并[1,5-a]嘧啶化合物抑制 mTOR 的方法，以及利用这些化合物治疗、预防、抑制或改善与 mTOR 相关的一种或多种疾病的方法。
• [EN] BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES EN TANT QU'INHIBITEURS DE PRODUCTION D'AUTOTAXINE (ATX) ET D'ACIDE LYSOPHOSPHATIDIQUE (LPA)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015144605A1

  公开（公告）日：2015-10-01

  The invention provides novel compounds having the general formula (I) wherein R1, R2, A, W, m, n, p and q are as described herein, compositions including the compounds. The compounds of formula (I) are useful as autotaxin (ATX) inhibitors which are inhibitors of lysophosphatidic acid (LPA) production and thus modulators of LPA levels and associated signaling; in particular they are useful for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection.

  该发明提供了具有通式（I）的新化合物，其中R1、R2、A、W、m、n、p和q如本文所述，包括这些化合物的组合物。通式（I）的化合物可用作自体税肽酶（ATX）抑制剂，这些抑制剂是溶磷脂酸（LPA）产生的抑制剂，从而调节LPA水平和相关信号传导；特别是它们可用于治疗或预防肾脏疾病、肝脏疾病、炎症性疾病、神经系统疾病、呼吸系统疾病、血管和心血管疾病、纤维化疾病、癌症、眼部疾病、代谢性疾病、胆汁淤积和其他形式的慢性瘙痒以及急性和慢性器官移植排斥反应的治疗。